Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + Lenalidomide in R/R DLBCL
NCT05552937Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Sep 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by InnoCare Pharma. Started Sep 2021; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05552937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552937.